Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Pollack

Showing results (11-20 of 265) with videos related to

Pageof 27
Sort By:
Lancet (London, England)|May 19, 2024
Androgen deprivation therapy combined with postoperative radiotherapy for prostate cancer managementAlan Pollack, Alan Dal Pra
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2016
Weighing the Addition of Androgen Suppression Therapy to Radiotherapy Dose Escalation for Intermediate-Risk Prostate CancerAlan Pollack, Matthew C Abramowitz
Nature Reviews. Urology|May 20, 2020
Using hormone therapy with salvage radiotherapy according to presalvage PSA levelsAlan Dal Pra, Alan Pollack
Nature Clinical Practice. Oncology|November 3, 2005
Is 6 months of androgen suppression therapy plus radiotherapy of benefit in patients with localized prostate cancer?Alan Pollack, Eric M Horwitz
Seminars in Radiation Oncology|December 18, 2007
Postprostatectomy radiation therapy for prostate cancerMatthew C Abramowitz, Alan Pollack
International Journal of Radiation Oncology, Biology, Physics|May 23, 2002
In regard to Sherertz et al., IJROBP 2001; 51:1241-1245Alan Pollack, Eric M Horwitz
Cancer|June 23, 2009
Predictive models in external beam radiotherapy for clinically localized prostate cancerMack Roach, Fred Waldman, Alan Pollack
The Prostate|July 15, 2005
Antisense Bcl-2 sensitizes prostate cancer cells to radiationZhaomei Mu, Paul Hachem, Alan Pollack
Seminars in Radiation Oncology|May 3, 2003
Treatment of prostate cancer with regional lymph node (N1) metastasisAlan Pollack, Eric M Horwitz, Ben Movsas
European Urology|December 17, 2018
Local Treatment in Metastatic Prostate Cancer: A Cultural Shift Confronts Power and SelectionAlan Dal Pra, Matthew Abramowitz, Alan Pollack
Pageof 27

Showing results (11-20 of 265) with videos related to

Sort By:
Pageof 27
Lancet (London, England)|May 19, 2024
Androgen deprivation therapy combined with postoperative radiotherapy for prostate cancer managementAlan Pollack, Alan Dal Pra
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2016
Weighing the Addition of Androgen Suppression Therapy to Radiotherapy Dose Escalation for Intermediate-Risk Prostate CancerAlan Pollack, Matthew C Abramowitz
Nature Reviews. Urology|May 20, 2020
Using hormone therapy with salvage radiotherapy according to presalvage PSA levelsAlan Dal Pra, Alan Pollack
Nature Clinical Practice. Oncology|November 3, 2005
Is 6 months of androgen suppression therapy plus radiotherapy of benefit in patients with localized prostate cancer?Alan Pollack, Eric M Horwitz
Seminars in Radiation Oncology|December 18, 2007
Postprostatectomy radiation therapy for prostate cancerMatthew C Abramowitz, Alan Pollack
International Journal of Radiation Oncology, Biology, Physics|May 23, 2002
In regard to Sherertz et al., IJROBP 2001; 51:1241-1245Alan Pollack, Eric M Horwitz
Cancer|June 23, 2009
Predictive models in external beam radiotherapy for clinically localized prostate cancerMack Roach, Fred Waldman, Alan Pollack
The Prostate|July 15, 2005
Antisense Bcl-2 sensitizes prostate cancer cells to radiationZhaomei Mu, Paul Hachem, Alan Pollack
Seminars in Radiation Oncology|May 3, 2003
Treatment of prostate cancer with regional lymph node (N1) metastasisAlan Pollack, Eric M Horwitz, Ben Movsas
European Urology|December 17, 2018
Local Treatment in Metastatic Prostate Cancer: A Cultural Shift Confronts Power and SelectionAlan Dal Pra, Matthew Abramowitz, Alan Pollack
Pageof 27